CSIMarket Company Name, Ticker, Suppliers, else..
 
Apogee Therapeutics Inc   (NASDAQ: APGE)
Other Ticker:  
 
 
Price: $40.1400 $0.25 0.627%
Day's High: $40.88 Week Perf: -0.57 %
Day's Low: $ 39.34 30 Day Perf: 21.42 %
Volume (M): 638 52 Wk High: $ 69.40
Volume (M$): $ 25,597 52 Wk Avg: $46.79
Open: $39.93 52 Wk Low: $29.10



 Market Capitalization (Millions $) 2,216
 Shares Outstanding (Millions) 55
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -182
 Cash Flow (TTM) (Millions $) 23
 Capital Exp. (TTM) (Millions $) 1

Apogee Therapeutics Inc
Apogee Therapeutics Inc. is a biotechnology company focused on the development of novel therapeutics for the treatment of various diseases. The company specializes in the discovery and development of small molecule drugs targeting specific biological pathways involved in disease processes. Apogee's goal is to create innovative and effective treatments that address unmet medical needs and improve patient outcomes. The company employs advanced technologies and collaborations with academic and industry partners to accelerate the development of their therapeutic candidates. Overall, Apogee Therapeutics aims to make a significant impact on the field of medicine by bringing new and improved treatments to patients worldwide.


   Company Address: 221 Crescent St Waltham 2453 MA
   Company Phone Number: 394?5230   Stock Exchange / Ticker: NASDAQ APGE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.02%    
BIIB        1.67% 
EXEL   -0.46%    
GILD        3.81% 
MRNA   -2.99%    
NVAX   -4.27%    
• View Complete Report
   



Clinical Study

---Abstract The landscape of therapeutic interventions for respiratory and inflammatory c...

Published Mon, Dec 30 2024 9:41 AM UTC

Title : Advancements in Respiratory Therapeutics: Apogee Therapeutics Doses First Participants in Phase 1 Clinical Trial of APG333 Abstract The landscape of therapeutic interventions for respiratory and inflammatory conditions has witnessed a significant advancement with the recent announcement by Apogee Therapeutics Inc. (NASDAQ: APGE) regarding the initiation of dosing i...
Product Service News

Apogee Therapeutics Pioneering a New Era in Inflammation & Immunology

Published Mon, Nov 18 2024 12:30 PM UTC

Revolutionizing Inflammation and Immunology: Insights from Apogee Therapeutics? Upcoming Virtual R&D Day In an era where innovation in drug development remains pivotal, Apogee Therapeutics is poised to make significant strides in the field of Inflammation and Immunology (I&I). As the company prepares for its inaugural virtual R&D day on December 2, 2024, it aims to highlight...
Clinical Study

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Published Wed, May 15 2024 8:01 PM UTC

Apogee Therapeutics Initiates Phase 2 Clinical Trial of APG777 for Atopic Dermatitis Following Promising Phase 1 Results Apogee Therapeutics recently announced the commencement of dosing in their Phase 2 clinical trial for APG777, a novel subcutaneous, half-life extended anti-IL-13 antibody. This drug is being investigated for the treatment of atopic dermatitis and oth...
Clinical Study

Apogee Therapeutics Breaks Ground with Promising Drug Pipeline and Strong Q1 2024 Performance: Eagerly Awaits Game-Changing Data for Atopic Dermatitis Treatment

Published Mon, May 13 2024 11:00 AM UTC

Apogee Therapeutics Advances Promising Drug Pipeline and Acknowledges Strong First Quarter 2024 Financial Performance: Anticipates Key Data Release for APG777 in Late 2025Apogee Therapeutics, a leading biopharmaceutical company, is making remarkable progress in its pursuit of innovative therapies for patients suffering from debilitating conditions. The company recently annou...
Clinical Study

APG808: A Promising Half-life Extended IL-4R Antibody for Improved Treatment of Inflammatory Diseases

Published Mon, Mar 25 2024 11:00 AM UTC

Apogee Therapeutics, a biopharmaceutical company, has announced the dosing of the first participants in a Phase 1 trial for APG808, a novel half-life extended IL-4R antibody. This antibody is being investigated for its potential in treating Chronic Obstructive Pulmonary Disease (COPD) and other inflammatory diseases.The preclinical data with APG808 has shown promising result...





  Apogee Therapeutics Inc Outlook

On May 13 2024 the Apogee Therapeutics Inc provided following guidance

Apogee Therapeutics Inc. has made significant progress in its pipeline, including the initiation of a Phase 2 clinical trial for APG777. This drug is a subcutaneous half-life extended monoclonal antibody that targets IL-13 and is being tested in patients with moderate-to-severe atopic dermatitis. The company expects to receive 16-week proof-of-concept data from Part A of the trial in the second half of 2025. This trial marks a significant milestone for Apogee Therapeutics as it continues to advance its pipeline of innovative therapies.

Additionally, Apogee Therapeutics reported its first quarter financial results for 2024. The company remains optimistic about its financial outlook and is committed to...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com